The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) is a cytosolic pattern recognition receptor (PRR) that recognizes multiple pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Once activated, NLRP3 initiates the inflammasome assembly together with the adaptor ASC and the effector caspase-1, leading to caspase-1 activation and subsequent cleavage of IL-1β and IL-18. Aberrant NLRP3 inflammasome activation is linked with the pathogenesis of multiple inflammatory diseases, such as cryopyrinassociated periodic syndromes, type 2 diabetes, non-alcoholic steatohepatitis, gout, and neurodegenerative diseases. Thus, NLRP3 is an important therapeutic target, and researchers are putting a lot of effort into developing its inhibitors. The review summarizes the latest advances in the mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., Zhuang, Y., Cai, T., Wang, F., & Shao, F. (2015) · Nature · doi:10.1038/nature15514 · Cited by 6,659 · cited 2×
“Gasdermin D (GSDMD) is reported to be the executor of pyroptosis induced by NLRP3 inflammasome agonists (53, 54).”
BackgroundMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 1×
“Once activated by an inflammatory ligand, inflammasomes trigger the auto-processing of caspase-1 into the catalytically active caspase-1, which mediates the cleavage of pro-IL-1b and pro-IL-18 (2, 3) and induces pyroptosis (4).”
BackgroundGout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · cited 2×
“Furthermore, it has been reported that cholesterol crystal, a hallmark of atherosclerotic lesions (80), activates NLRP3 inflammasome in a process involving lysosomal rupture, and reconstitution with NLRP3-, ASC-, or IL-1a/b–deficient bone marrow in low-density lipoprotein receptor (LDLR)–deficient mice shows reduced e…”
BackgroundInflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · cited 2×
“In vitro, GSDMD-N is found to kill cell-free bacteria, implying its direct bactericidal effect but further study is needed (56).”
BackgroundHornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065 · cited 2×
“In a study, sterile lysosomal rupture caused by Leu-LeuOMe (L-leucyl-L-leucine methyl ester) is sufficient to trigger NLRP3 inflammasome activation, whereas suppression of phagosomal acidification or cathepsin B (using Ca074Me as the inhibitor) blocks NLRP3 activation (43).”
BackgroundNakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 1×
“Ab activates NLRP3 in a process engaging the lysosomal damage and cathepsin B release (45); cleaved caspase-1 is increased in amyloid-plaque in mice and patients with AD (10, 45).”
BackgroundA small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Pore-forming activity and structural autoinhibition of the gasdermin family
Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J., Sun, H., Wang, D.-C., & Shao, F. (2016) · Nature · doi:10.1038/nature18590 · Cited by 2,771 · cited 1×
“GSDMD-N domain possesses the pyroptosis-inducing activity and is inhibited by its C domain (GSDMD-C), upon inflammasome activation, caspase-1 cleaves GSDMD into two parts, the free GSDMD-N oligomerizes in membranes to form pores, thus killing cells from inside (55, 56).”
BackgroundThe NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655 · cited 1×
“With the discovery that NLRP3 inflammasome mediates caspase-1 activation and IL-1b maturation, its relation with insulin resistance and type 2 diabetes development has been recognized (13, 95–97); NLRP3 deficiency protects mice from obesity-induced insulin resistance (13, 96).”
BackgroundInflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570 · cited 2×
“With the discovery that NLRP3 inflammasome mediates caspase-1 activation and IL-1b maturation, its relation with insulin resistance and type 2 diabetes development has been recognized (13, 95–97); NLRP3 deficiency protects mice from obesity-induced insulin resistance (13, 96). frontiersin.org Moreover, the level of pl…”
BackgroundNon-canonical inflammasome activation targets caspase-11
Kayagaki, N., Warming, S., Lamkanfi, M., Walle, L. V., Louie, S., Dong, J., Newton, K., Qu, Y., Liu, J., Heldens, S., et al. (2011) · Nature · doi:10.1038/nature10558 · Cited by 2,530 · cited 1×
“The non-canonical inflammasome refers to the caspase-11– dependent inflammasome (Figure 3) (58).”
BackgroundGasdermin D is an executor of pyroptosis and required for interleukin-1β secretion
He, W.-T., Wan, H., Hu, L., Chen, P., Wang, X., Huang, Z., Yang, Z.-H., Zhong, C.-Q., & Han, J. (2015) · Cell Research · doi:10.1038/cr.2015.139 · Cited by 2,517
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
Inflammatory caspases are innate immune receptors for intracellular LPS
Shi, J., Zhao, Y., Wang, Y., Gao, W., Ding, J., Li, P., Hu, L., & Shao, F. (2014) · Nature · doi:10.1038/nature13683 · Cited by 2,285
Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis
Shimada, K., Crother, T. R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S., Ramanujan, V. K., Wolf, A. J., Vergnes, L., Ojcius, D. M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.009 · Cited by 2,282 · cited 1×
“AIM2 inflammasome is also responsible for dsDNA recognition; however, oxidized mtDNA preferentially triggers NLRP3 not AIM2 inflammasome (48).”
BackgroundThe ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172 · cited 2×
“The protective role of BHB in NLRP3-driven diseases such as Muckle–Wells syndrome, urate crystal–induced peritonitis, and familial cold autoinflammatory syndrome has been validated in rodent models (133).”
BackgroundTargeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 1×
“IL-1b is reported to inhibit insulin signaling (92–94); randomized clinical trials shows that blocking IL-1b signaling (using recombinant human IL-1 receptor antagonist) is effective in type 2 diabetes (94).”
BackgroundThe Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996) · Science · doi:10.1126/science.272.5262.735 · Cited by 1,739
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101405 · Cited by 1,618
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493
NLRP3 inflammasome activation drives tau pathology
Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., et al. (2019) · Nature · doi:10.1038/s41586-019-1769-z · Cited by 1,487 · cited 1×
“Moreover, a recent study demonstrates the pivotal role NLRP3 in tau pathology; NLRP3 can be activated by tau monomers and oligomers, then inducing tau hyperphosphorylation and aggregation possibly via regulation of tau kinase (104).”
BackgroundMolecular mechanisms regulating NLRP3 inflammasome activation
Jo, E.-K., Kim, J. K., Shin, D.-M., & Sasakawa, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.95 · Cited by 1,378
Unified Polymerization Mechanism for the Assembly of ASC-Dependent Inflammasomes
Lu, A., Magupalli, V. G., Ruan, J., Yin, Q., Atianand, M. K., Vos, M. R., Schröder, G. F., Fitzgerald, K. A., Wu, H., & Egelman, E. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.008 · Cited by 1,353
NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux
He, Y., Zeng, M. Y., Yang, D., Motro, B., & Núñez, G. (2016) · Nature · doi:10.1038/nature16959 · Cited by 1,295 · cited 2×
“Frontiers in Immunology 02 component of NLRP3 inflammasome (19).”
BackgroundNew mitochondrial DNA synthesis enables NLRP3 inflammasome activation
Zhong, Z., Liang, S., Sanchez-Lopez, E., He, F., Shalapour, S., Lin, X.-J., Wong, J., Ding, S., Seki, E., Schnabl, B., et al. (2018) · Nature · doi:10.1038/s41586-018-0372-z · Cited by 1,208 · cited 1×
“CMPK2 is an enzyme that supplies deoxyribonucleotides for mtDNA synthesis, TLR signals via Myd88 and TRIF induce IRF1-dependent transcription of CAMK2, and CAMK2-mediated mtDNA synthesis is required for oxidized mtDNA generation induced by NLRP3 agonists (49).”
BackgroundThe Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages
Evavold, C. L., Ruan, J., Tan, Y., Xia, S., Wu, H., & Kagan, J. C. (2018) · Immunity · doi:10.1016/j.immuni.2017.11.013 · Cited by 1,115 · cited 1×
“Moreover, it is demonstrated that GSDMD mediates IL-1b release from living macrophages under the hyperactivation state, GSDMD pores on the membrane facilitate and acts as a conduit for IL-1b secretion (57).”
BackgroundNLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110 · cited 1×
“During the last few years, increasing evidences illustrate the role of NLRP3 in NASH (83–85), elevated hepatic expression of Nlrp3, Asc, and Casp1 associates with liver inflammation in dietary and nutrient deficiency fatty liver diseases (84, 86–88), and NLRP3 activation is critical for progression of NASH evidenced b…”
BackgroundMicroglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983 · cited 1×
“In a model of AD, deficiency of ASC or NLRP3 alleviates amyloid plaque pathology (103), implying that NLRP3 is critical in the progression of amyloid-beta pathology.”
BackgroundKetone bodies as signaling metabolites
Newman, J. C., & Verdin, E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.002 · Cited by 966
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Sheedy, F. J., Grebe, A., Rayner, K. J., Kalantari, P., Ramkhelawon, B., Carpenter, S. B., Becker, C. E., Ediriweera, H. N., Mullick, A. E., Golenbock, D. T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2639 · Cited by 935 · cited 1×
“Upon response to oxLDL, CD36 also cooperates with TLR4TLR6 to activate the priming signal to induce expression of NLRP3 and pro–IL-1b (81).”
BackgroundInflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869 · cited 1×
“recombinant form of IL-1RA (Anakinra) (74), the anti-IL-1b monoclonal antibody (Canakinumab) (75), and the dimeric IL-1 receptor fusion protein (Rilonacept) (76).”
BackgroundStructural mechanism for NEK7-licensed activation of NLRP3 inflammasome
Sharif, H., Wang, L., Wang, W. L., Magupalli, V. G., Andreeva, L., Qiao, Q., Hauenstein, A. V., Wu, Z., Núñez, G., Mao, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1295-z · Cited by 824 · cited 1×
“The specific structural mechanism of NEK7-licensed NLRP3 inflammasome activation has been revealed by Sharif and colleagues (22).”
BackgroundGlyburide inhibits the Cryopyrin/Nalp3 inflammasome
Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., & Dixit, V. M. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200903124 · Cited by 820 · cited 3×
“Several studies report that Glyburide reduces a variety of NLRP3dependent pathologies such as septic shock, bronchopulmonary dysplasia and Cutaneous leishmaniasis (119, 120, 122).”
BackgroundInflammasome is a central player in the induction of obesity and insulin resistance
Stienstra, R., van Diepen, J. A., Tack, C. J., Zaki, M. H., van de Veerdonk, F. L., Perera, D., Neale, G. A., Hooiveld, G. J., Hijmans, A., Vroegrijk, I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100255108 · Cited by 727
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011) · Hepatology · doi:10.1002/hep.24341 · Cited by 645
An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells
Zanoni, I., Tan, Y., Di Gioia, M., Broggi, A., Ruan, J., Shi, J., Donado, C. A., Shao, F., Wu, H., Springstead, J. R., et al. (2016) · Science · doi:10.1126/science.aaf3036 · Cited by 583 · cited 1×
“Oxidized phospholipids (oxPAPC), one class of DAMPs, can bind to caspase11 and induce inflammasome activation, but oxPAPC only induces caspase-11–dependent IL-1 release, but not pyroptosis (64).”
BackgroundHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
NLRP3 inflammasome activation is required for fibrosis development in NAFLD
Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1170-1 · Cited by 486 · cited 1×
“During the last few years, increasing evidences illustrate the role of NLRP3 in NASH (83–85), elevated hepatic expression of Nlrp3, Asc, and Casp1 associates with liver inflammation in dietary and nutrient deficiency fatty liver diseases (84, 86–88), and NLRP3 activation is critical for progression of NASH evidenced b…”
BackgroundErratum: Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.149 · Cited by 465
Homeostasis-altering molecular processes as mechanisms of inflammasome activation
Liston, A., & Masters, S. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.151 · Cited by 459 · cited 1×
“Upon responding to stimuli that cause loss of autoinhibition (15), NLRP3 oligomerizes through interactions between NACHT domains, then recruiting ASC via PYD-PYD interactions, ASC self-associates into helical filaments, which further form a single macromolecular focustermed ASC speck (16–18).”
BackgroundThe NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426 · cited 2×
“OLT1177 is now tested in clinic to treat acute gout flares and heart failure (78).”
BackgroundMitochondrial reactive oxygen species and Ca 2+ signaling
Camello-Almaraz, C., Gomez-Pinilla, P. J., Pozo, M. J., & Camello, P. J. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00217.2006 · Cited by 336
Multiple cathepsins promote pro-IL-1β synthesis and NLRP3-mediated IL-1β activation
Orlowski, G. M., Colbert, J. D., Sharma, S., Bogyo, M., Robertson, S. A., & Rock, K. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500509 · Cited by 268 · cited 1×
“mediated by several redundant cathepsins (including cathepsin B) (46).”
Background
Cited by
A guide to cell death pathways
Yuan, J., & Ofengeim, D. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00689-6 · Cited by 933
DAMPs and DAMP-sensing receptors in inflammation and diseases
Ma, M., Jiang, W., & Zhou, R. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.002 · Cited by 515
Chiang, M.-C., Tsai, T.-Y., & Wang, C.-J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076328 · Cited by 231
Cheng, Y., Jung, J., Guo, L., Shuboni-Mulligan, D. D., Chen, J.-F., Hu, W., & Guo, M.-L. (2025) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2024.09.011 · Cited by 16
Metadata
- Authors
- Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-18
- Volume
- 13
- Pages
- 1109938-1109938
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4317396180
- Cited by
- 181
- References
- 53
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.